Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic ...
Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients ...
Certainly also drugs that interact with DNA damage and repair. PARP inhibitors have a very fixed now role in how we take care ...
“Blinatumomab is excellent at eradicating MRD in a [patient with] MRD-positive [disease], regardless of which ALL it is, ...
Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in ...
Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and ...
Matulonis, MD, broke down the trial design, backbone regimen, and preclinical rationale that she believes made KEYNOTE-B96 a ...
You're absolutely correct. The more recent approvals have certainly been for mirvetuximab [soravtansine] for our patients ...
Panelists discuss which patients at first relapse make them think of CAR T-cell therapy and which make them pause, including ...
The faculty consider how they would answer a patient who is 5 years out from a single infusion in sustained MRD-negative ...
The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and ...
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results